Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03070964 · ClinicalTrials.gov registry record · Phase 2
A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
A Phase 2 study, sponsored by PharmaMar.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT03070964 is a Phase 2 study that was terminated before completion, run by PharmaMar. The registered enrollment target is 14 participants.
The verdict
NCT03070964, a Phase 2 study, was terminated before completion, sponsored by PharmaMar.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
Prospective, multicenter, phase II clinical trial to determine the efficacy of plitidepsin in patients with relapsed/refractory (R/R) angioimmunoblastic Tcell lymphoma (AITL).This is an international, multicenter study (with approximately 17 investigative sites).
Interventions
- DRUG plitidepsin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-10-25 |
| Est. Completion | 2018-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03070964
The ClinicalTrials.gov registry entry for NCT03070964 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which plitidepsin is the first listed.
NCT03070964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03070964 about?
NCT03070964 is a clinical study titled "A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma". Prospective, multicenter, phase II clinical trial to determine the efficacy of plitidepsin in patients with relapsed/refractory (R/R) angioimmunoblastic Tcell lymphoma (AITL).This is an international, multicenter study (with approximately 17 investigative sites).
What is the current status of trial NCT03070964?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2016-10-25. Estimated completion is 2018-07.
What interventions are being tested in trial NCT03070964?
The interventions under investigation include: plitidepsin (DRUG).
Who is sponsoring clinical trial NCT03070964?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.